Payment overview · 2025
General Payments
$134.46
6 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Marcus Causey, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLORADO SPRINGS, CO · NPI 1033180963
Verified facts
What the public records show
CMS Open Payments records show Robert Marcus Causey, MD received $134.46 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.29 | 28.5% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $35.67 | 26.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.59 | 23.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.91 | 21.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.79 | 5 |
| Long term medical supply or device loan | $35.67 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Spot Vision Screener Normalized: hillrom spot vision screener |
Device | Baxter Healthcare | $35.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 99 |
| Lisinopril | Lisinopril | 320 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 39 |
| Omeprazole | Omeprazole | 207 | 47 |
| Gabapentin | Gabapentin | 187 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 32 |
| Metformin Hcl | Metformin Hcl | 166 | 40 |
| Losartan Potassium | Losartan Potassium | 136 | 31 |
| Trazodone Hcl | Trazodone Hcl | 134 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 32 |
| Montelukast Sodium | Montelukast Sodium | 95 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 15 |
| Naproxen | Naproxen | 77 | 30 |
| Ezetimibe | Ezetimibe | 76 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 17 |
| Furosemide | Furosemide | 69 | 16 |
| Pregabalin | Pregabalin | 68 | 11 |
| Simvastatin | Simvastatin | 65 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 12 |
| Meloxicam | Meloxicam | 54 | 13 |
| Tramadol Hcl | Tramadol Hcl | 53 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 11 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Carvedilol | Carvedilol | 43 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 17 |
| Glipizide | Glipizide | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Prednisone | Prednisone | 41 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 12 |
| Baclofen | Baclofen | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Eliquis | Apixaban | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134.46 · 6 records | Abbott Laboratories | AIRSUPRA, BREZTRI, FREESTYLE LIBRE, Hillrom - Spot Vision Screener, Ozempic, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error